Ураження нервової системи при системному червоному вовчаку: аспекти патогенезу, поширеність, погляди на класифікацію клінічних виявів
DOI:
https://doi.org/10.30978/UNZ2018225Ключові слова:
нейропсихіатричний системний червоний вовчак, автоантитіла, судинний механізм, класифікація неврологічних виявівАнотація
Системний червоний вовчак — автоімунне захворювання, яке уражає майже всі системи органів, зокрема нервову систему, про що свідчить висока частота неврологічної симптоматики. Висвітлено сучасні погляди щодо можливих патогенетичних механізмів ураження нервової системи при системному червоному вовчаку. Розглянуто дані щодо фактичної поширеності неврологічних виявів у цієї категорії пацієнтів. Наведено відомості щодо класифікації неврологічних виявів вовчака.
Посилання
Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus. 2003;12:908-915.
Ainiala H, Loukkola J, Peltola J et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496-500.
Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61:822-829.
Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm. 2013;120:1579-1589.
Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. interactions of inflammatory cells and activated endothelium. Arthritis Rheum. 1996;39:9-22.
Borowoy AM, Pope JE, Silverman E et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum — 2012;42(2):179-185.
Bortoluzzi A, Scire CA, Bombardieri S et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54:891-898.
Dale RC, Yin K, Ding A et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol. 2011;53:522-528.
Ellyard JI, Jerjen R, Martin JL et al. Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing. Arthritis Rheumatol. 2014;66 (12):3382-3386.
Galanaud D, Dormont D, Marsault C et al. Brain MRI in patients with past lupus-associated chorea. Stroke. 2000;31:3079-3083.
Govoni M, Bortoluzzi A, Padovan M et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72.
Gulati G, Iffland PH, Janigro D et al. Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction. Clin Rheumatol. 2016;35:2989-2997.
Hanly JG. Neuropsychiatric lupus. Curr Rheumatol Rep. 2001;3(3):205-212.
Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-347.
Hanly JG, Urowitz MB, O’Keeffe AG et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013;65:2887-2897.
Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum. 2007;56:265-273.
Hanly JG, Urowitz MB, Su L. Prospective analysis of neuropsychiatric events in an international disease inception cohort of SLE patients. Ann Rheum Dis. 2010;69(3):529-535.
Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19:732-741.
Harrison M, Ravdin L, Volpe B et al. Anti-NR2 antibody does not identify cognitive impairment in a general SLE population. Arthritis Rheum. 2004;50:596.
Hirohata S, Sakuma Y, Yanagida T, Yoshio T. Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. Arthritis Res Ther. 2014;16:450.
Hu C, Huang W, Chen H et al. Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus. PLoS One. 2015;10. e0126643.
Huang X, Magder LS, Petri M. Predictors of incident depression in systemic lupus erythematosus. J Rheumatol. 2014;41:1823-1833.
Husebye ES, Sthoeger ZM, Dayan M et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1210-1213.
Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10 (10):579-596.
Kampylafka EI, Alexopoulos H, Kosmidis ML et al. Incidence and prevalence of major central nervous system involvement in SLE: a 3-year prospective study of 370 patients. PLoS One. 2013;8(2). e55843.
Lapteva L, Nowak M, Yarboro CH et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2505-2514.
Lundstrom E, Gustafsson JT, Jonsen A et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2013;72(6):1018-1025.
Magro Checa C, Cohen D, Bollen EL.E. M. et al. Demyelinating disease in SLE: is it multiple sclerosis or lupus?. Best Pract Res Clin Rheumatol. 2013;27:405-424.
Maneeton B, Maneeton N, Louthrenoo W. Prevalence and predictors of depression in patients with systemic lupus erythematosus: a cross-sectional study. Neuropsychiatr Dis Treat. 2013;9:799-804.
Matsuura E, Hughes GR.V., Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev. 2008;7:558-566.
Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127:1200-1209.
Noureldine MH, Harifi G, Berjawi A et al. Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?. Lupus. 2016;25 (13):1397-1411.
Omdal R, Brokstad K, Waterloo K et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol. 2005;12:392-398.
Petri M, Orbai A.-M., Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-2686.
Sciascia S, Bertolaccini ML, Roccatello D et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol. 2014;261(9):1706-1714.
Timlin H, Petri M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus. 2013;22:1251-1258.
Unterman A, Nolte JE, Boaz M et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1-11.
Uthman I, Noureldine MH, Berjawi A et al. Hughes syndrome and multiple sclerosis. Lupus. 2014;24:115-121.
Zaccagni H, Fried J, Cornell J et al. Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Frontiers in Bioscience. 2004;9:1654-1661.
